Research units

Simicek Lab

The Simicek lab is applying state-of-the-art genomic, proteomic and cell-based methods to study fundamental molecular processes linked to immunoreceptors and surface proteins that represent important targets for modern immunotherapy. The team is also developing novel approaches to enhance the therapeutic potential of chimeric antigen receptor (CAR) T-cells. Particular focus is put on  the creation of new CARs, hybrid T-cell receptors, site-specific gene editing (knock-in/knock-out) in primary T-cells and pre-clinical vivo models. The ultimate goal is a fast transfer of the knowledge into the stage of clinical study in patients with haematological malignancies.

Team leader: Assoc. Prof. Michal Šimíček

Jelinek Lab

Under the expert guidance of Assoc. Prof. Jelinek, the laboratory is dedicated to advancing multiple myeloma research through a multifaceted approach. Specializing in the processing of patient tumor samples, the lab employs cutting-edge techniques like spectral flow cytometry and single cell RNA sequencing. Driven by a commitment to precision medicine, the team conducts rigorous bioinformatic and biostatistical analyses, unraveling the molecular complexities of multiple myeloma. What sets this lab apart is its seamless collaboration between clinical and research teams. By leveraging this close partnership, Jelinek’s lab not only pioneers discoveries of novel predictive and treatment targets but also accelerates the translation of these findings into tangible benefits for multiple myeloma patients.

Team leader: Assoc. Prof. Tomáš Jelínek, M.D., Ph.D.

Chyra Lab


Team leader: Zuzana Chyra, Ph.D.

Scroll to Top